Roles of Non-cholinergic Intrapancreatic Nerves, Serotonergic Nerves, on Pancreatic Exocrine Secretion in the Isolated Perfused Rat Pancreas

Zheng er Jiang¹, Bich-Na Shin², In-Hye Kim², Hyun Joo Lee³, Jun-Hwan Yong³, Min-Jae Lee⁴, Moo-Ho Won⁵, and Yun-Lyul Lee²

¹Department of Physiology, College of Nursing, Yanbian University, Yanji 133000, China, ²Department of Physiology, College of Medicine, Hallym University, Chuncheon 200-702, ³Department of Occupational Therapy, Dongnam Health College, Suwon 440-714, ⁴Department of Veterinary Lab. Animal Medicine & Science, College of Animal Resource Science, ⁵Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon 200-701, Korea

It has been reported that axons which display 5-hydroxytryptamine (5-HT) immunoreactivity are abundant in the pancreas and the majority of serotonergic axons terminate within intrapancreatic ganglia, islet and acini. This histological result strongly suggests that intrapancreatic serotonergic nerves could affect to the pancreatic endocrine and exocrine secretion. Thus, this study was aimed to investigate whether intrapancreatic serotonergic nerves could affect pancreatic exocrine secretion and an action mechanism of the intrapancreatic serotonergic nerves. The rats were anesthetized with a single injection of urethane. The median line and the abdominal aorta was carefully dissected and cannulated with PE-50 tubing just above the celiac artery, and then tightly ligated just below the superior mesenteric artery. The pancreatic duct was also cannulated with Tygon microbore tubing. With the addition of serotonin, pancreatic volume flow and amylase output were significantly inhibited electrical field stimulation (EFS). On the other hand, pancreatic volume flow and amylase output were significantly elevated in EFS with the addition of spiperone. EFS application, however, pancreatic volume flow and amylase output had no significant change in cholecystokinin (CCK) alone when serotonin was applied under a 5.6 mM glucose background. Pancreatic volume flow and amylase output under 18 mM glucose background were significantly elevated in CCK plus serotonin than in CCK alone. These data suggest that intrapancreatic serotonergic nerves play an inhibitory role in pancreatic exocrine secretion and an important role in the insulin action or release.

Key Words: Intrapancreatic nerve, Electrical stimulation, 5-hydroxytryptamine, Cholecystokinin, Insulin

INTRODUCTION

Serotonin (5-hydroxytryptamine; 5-HT) is synthesized and released in platelets of enterochromaffin cells of the gastrointestinal mucosa. A small quantity of serotonin exists in the central nervous system [1] and most of serotonin exists in the myenteric plexus of the gastrointestinal system [2]. Although most serotonin exists in the gastrointestinal tract, the roles of serotonin in the gut are still unclear. It is mainly reported that roles of serotonin released from enteric nervous system or enterochromaffin cells in the intestinal mucosa [3]. Thus this study was focused to fined whether intrapancreatic serotonergic nerves could affect pancreatic exocrine secretion in the ex vivo model.

The pancreas is a unique organ which has both endocrine and exocrine functions in the body. Over 20 kinds of digestive enzymes, including bicarbonate and water, are secreted from the exocrine part for digestion of foods. Moreover, insulin, glucagon, somatostatin and pancreatic polypeptide are also secreted from the endocrine part. In spite of these dual actions of the pancreas, the effect of serotonin on the pancreas has been controversial. It has been reported that axons which display 5-HT immunoreactivity are abundant in the pancreas and the majority of serotonergic axons terminate within intrapancreatic ganglia, islet, and acini [4]. These histological results strongly suggest that intrapancreatic serotonergic nerves could affect pancreatic endocrine and exocrine secretion.

Pancreatic exocrine secretion is regulated by the autonomic nerve system and gastrointestinal hormones. Recently, it has been reported that pancreatic exocrine secretion is regulated by the interaction of hormones and the neural system [5]. In addition, pancreatic exocrine secretion is affected by pancreatic islet hormones such as insulin and, somatostatin [6]. As seen in the above results and reports, pancreatic exocrine secretion is controlled by a complex set of factors. Pancreatic exocrine secretion was enhanced by

ABBREVIATIONS: 5-HT, 5-hydroxytryptamine; EFS, electrical field stimulation; CCK, cholecystokinin.
electrical stimulation (EFS) of the vagus nerve, but this enhanced effect was partly blocked by atropine, a muscarinic receptor antagonist [7]. EFS on rat pancreas enhanced pancreatic exocrine secretion by activation of the intrapancreatic nervous system [8,9]. Pre-treatment of atropine partly blocked this effect, but pre-treatment of tetrodotoxin, a nerve blocker, perfectly blocked it [10]. These results suggested that the non-cholinergic nerve system exists in the intrapancreatic nervous system, and it could affect the pancreatic exocrine secretion. There are both peptidergic nerves and cholinergic nerves in the intrapancreatic nervous system [11]. The serotonergic nerve is involved in the peptidergic nerve system [12] and may participate in pancreatic exocrine secretion. Because the axons of serotonergic nerve are distributed close to the non-serotonergic intrapancreatic nerves (mainly cholinergic nerve), the serotonergic nerves can affect pancreatic exocrine secretion indirectly via the affect of the cholinergic nerve. In addition, the serotonergic nerve can affect pancreatic exocrine secretion directly via the affect of the acini and islet cell because the axons of the serotonergic nerves are distributed near acini and islet cells [12]. Thus, this study was aimed to investigate whether intrapancreatic serotonergic nerves could affect pancreatic exocrine secretion and an action mechanism of the intrapancreatic serotonergic nerves.

METHODS

Experimental animals

Sprague-Dawley rats were used in the experiment which succeeded in experimental animal center of Hallym University. The environment of breeding room was maintained at condition that temperature was 23±2°C and relative humidity was 55±10%. Artificial lighting maintained 12 hours per day. The rats were anesthetized with a single intraperitoneal injection of 20% urethane (Sigma, USA) at a dose of 0.7 ml/100 g of body weight. The rats were sacrificed by an intravenous overdose injection of urethane after iso-
was < 0.05.

**RESULTS**

**Effects of serotonin on EFS-induced pancreatic exocrine secretion**

To investigate effects of serotonin (5-HT) on EFS-induced pancreatic exocrine secretion, serotonin (Sigma, USA) at a concentration of 2 μM was perfused with the perfusate containing 5.6 mM glucose from 45 min earlier EFS applied to the end of the experiment, during total 90 min.

When EFS was applied to the pancreas as shown Fig. 1, pancreatic flow rate and amylase output were increased. Pancreatic flow rate was elevated from 1.29±0.20 μl/15 min in basal to 6.69±1.23 μl/15 min in peak level. Amylase output was elevated from 11.47±2.91 μl/15 min to 49.71±8.24 μl/15 min in peak level. When serotonin was added to the perfusate, however, the flow rate and amylase output were markedly decreased. Pancreatic flow rate was decreased from 6.69±1.23 μl/15 min to 4.02±0.31 μl/15 min in peak level. Amylase output was also decreased from 49.71±8.24 μl/15 min to 21.58±2.92 μl/15 min in peak level.

**Effects of serotonin antagonist on EFS-induced pancreatic exocrine secretion**

To investigate effects of serotonin antagonist on EFS-induced pancreatic exocrine secretion, spiperone hydrochloride (Tocris, USA), 5-HT2A serotonin antagonist, at a concentration of 5 μM was perfused with the perfusate containing 5.6 mM glucose from 45 min earlier EFS applied to the end of the experiment.

When EFS applied to the pancreas as shown Fig. 2, pancreatic flow rate and amylase output were increased. Pancreatic flow rate was elevated from 1.18±0.09 μl/15 min to 5.55±0.92 μl/15 min in peak level. Amylase output was elevated from 9.86±2.88 μl/15 min to 45.74±9.42 μl/15 min in peak level. Pancreatic flow rate of EFS plus spiperone was elevated from 1.24±0.20 μl/15 min to 9.22±0.57 μl/15 min in peak level. Amylase output of EFS plus spiperone was elevated from 17.56±2.81 μl/15 min to 205.42±28.60 μl/15 min in peak level. Pancreatic volume flow was significantly elevated in EFS plus spiperone from after 30 min EFS applied to the end of this experiment than in EFS alone (p < 0.05). Pancreatic amylase output was significantly elevated in EFS plus spiperone than EFS alone during EFS applied 45 min (p < 0.05).

**Effects of serotonin antagonist with atropine on EFS-induced pancreatic exocrine secretion**

To investigate effects of serotonin on EFS-induced pancreatic exocrine secretion with atropine, atropine at a concentration of 2 μM was perfused with the perfusate containing 5.6 mM glucose with or without spiperone hydrochloride.

Pancreatic flow rate of EFS plus atropine was from 0.76±0.09 μl/15 min elevated to 2.99±0.51 μl/15 min in peak level. Amylase output of EFS plus atropine was also elevated from 8.08±1.78 μl/15 min to 23.66±8.37 μl/15 min in peak level.
Pancreatic volume flow of CCK plus serotonin was elevated 18.25±4.58 μl/15 min in peak level. Amylase output was also elevated from 1.08±0.25 μl/15 min to 6.67±0.65 μl/15 min in peak level. Amylase output of EFS plus serotonin and atropine was also elevated from 10.74±2.33 μl/15 min to 117.36±36.35 μl/15 min in peak level (Fig. 3). Pancreatic volume flow and amylase output were significantly higher in EFS plus serotonin and atropine than in EFS plus atropine during EFS applied 45 min (p<0.05).

**Effects of serotonin on CCK-induced pancreatic exocrine secretion under 5.6 mM glucose background**

To investigate effects of serotonin on CCK-induced pancreatic exocrine secretion, serotonin at a concentration of 2 μM was perfused with the perfusate containing 5.6 mM glucose during 105 min from 45 min before administration of CCK-8 to the end of this experiment.

Administration of CCK to the perfusate stimulated the pancreatic flow rate and amylase output. Pancreatic flow rate was elevated from 1.08±0.24 μl/15 min to 4.80±0.62 μl/15 min in peak level. Amylase output was also elevated from 18.25±4.58 μl/15 min to 48.49±9.51 μl/15 min in peak level. Pancreatic volume flow of CCK plus serotonin was elevated from 1.34±0.26 μl/15 min to 5.92±0.54 μl/15 in peak level. Amylase output of CCK plus serotonin was also elevated from 14.09±4.53 μl/15 min to 57.78±6.06 μl/15 min in peak level. Pancreatic volume flow and amylase output had no significance between in CCK alone and in CCK plus serotonin under the 5.6 mM glucose background (Fig. 4).

**Effects of serotonin on CCK-induced pancreatic exocrine secretion under 18 mM glucose background**

To investigate effects of serotonin on CCK-induced pancreatic exocrine secretion under 18 mM glucose background, serotonin at a concentration of 2 μM was perfused with the perfusate containing 18 mM glucose during 105 min from 45 min before administration of CCK-8 to the end of this experiment.

When CCK administrated to the perfusate under 18 mM glucose background as shown Fig. 5, pancreatic flow rate and amylase output were increased. Pancreatic flow rate was elevated from 1.25±0.22 μl/15 min to 8.10±0.98 μl/15 in peak level. Amylase output was also elevated from 20.39±6.22 μl/15 min to 140.07±21.91 μl/15 min in peak level. These values represent that endogenous insulin potentiated the action of CCK in pancreatic flow rate and amylase output (Fig. 4, 5).

Pancreatic volume flow of CCK plus serotonin under 18 mM glucose background was elevated from 1.42±0.25 μl/15 min to 5.04±0.73 μl/15 in peak level. Amylase output of CCK plus serotonin under 18 mM glucose background was also elevated from 11.72±3.48 μl/15 min to 35.73±8.57 μl/15 min in peak level. As shown in Fig. 5, these values of pancreatic volume flow and amylase output under 18 mM glucose background were significantly inhibited by administration of serotonin (p<0.05).

**DISCUSSION**

In the present study, EFS-induced pancreatic exocrine secretion in the isolated perfused rat pancreas was inhibited by serotonin, including volume flow and amylase output. Sipiperone hydrochloride, a serotonin antagonist, significantly enhanced pancreatic secretion of both fluid and amylase. The previous report states that 5-HT3 receptor antagonists significantly increased pancreatic fluid and protein outputs [14]. These results indicate that serotonin is involved in regulation of pancreatic secretion. EFS-induced pancreatic exocrine secretion was completely blocked by tetrodotoxin and partially inhibited by atropine [10]. Similarly, sipiperone hydrochloride-induced pancreatic exocrine secretion was partially inhibited by atropine in this study. These results agree with previous reports that 5-HT1 receptor agonist produced a dose-related inhibition of pancreatic exocrine secretion through a modulation of the vagal cholinergic pathway [15]. On the other hand, it is reported that 5-HT2 and 5-HT3 receptor antagonists inhibited pancreatic exocrine secretion [16]. These results are in opposition to our present study. The reason is that they put emphasis on pancreatic exocrine secretion of fluid thus investigated acid-induced pancreatic secretion. However, our
study put emphasis on pancreatic exocrine secretion of fluid and amylase output, therefore investigating EFS-induced pancreatic exocrine secretion.

This present study shows that pancreatic exocrine secretion in the isolated perfused rat pancreas had no significant difference between CCK alone administration and CCK plus serotonin administration when perfused with glucose at a dose of 5.6 mM. Interestingly, pancreatic exocrine secretion significantly inhibited by administration of serotonin when perfused with a high concentration of glucose, at a dose of 18 mM, prompted endogenous insulin secretion. These data suggest that action of serotonin on pancreatic exocrine secretion is dependent on insulin. This is in agreement with the finding that the neural 5-HT1 receptor was involved in the control of endocrine pancreatic function [17]. The pancreas has a portal system called the ‘insulo-acinar axis’ between the endocrine part and the exocrine part. In a rat, about 6% of the total pancreatic blood flow passes through this insulo-acinar axis [18]. For this insulo-acinar axis, pancreatic islet hormones can affect pancreatic exocrine secretion. Insulin enhanced the action of CCK [19,20] and the interaction of CCK and secretin enhanced pancreatic enzyme secretion mediated by insulin [21].

An action of serotonin on the insulin release or insulin action is still inconsistent. Both stimulatory [22,23] and inhibitory effects have been published. The inhibitory reports used an in vitro perfused islet cell model, so this different method made different results. As an ex vivo model, the isolated perfused rat pancreas model was used in this study. Isolated perfused rat pancreas model could eliminate effects of all external nerves and other gastrointestinal hormones perfectly. It is quite effective to know the role of a single nerve fiber or hormone. The pancreas can maintain its exocrine secretion with perfect isolation of external nerves as intrapancreatic nerves continue basal activity [24]. Thus an isolated perfused rat model is the proper model to study intrapancreatic nerves.

The controversial results might be based on the fact that serotonin plays a main role in insulin release. The present study also shows serotonin has a relationship with insulin. By using the isolated perfused rat pancreas model, all other effects can be eliminated. Therefore this study suggests serotonin has an inhibitory role in insulin release. On the contrary, 5-HT elicited marked increases in insulin secretion from normal pancreas but had an inhibitory effect on insulin secretion from diabetic pancreatic tissues [25]. This report shows another possibility that serotonin can have both an inhibitory and stimulatory effect on insulin release.

These data suggest that intrapancreatic serotonergic nerves play an inhibitory role in pancreatic exocrine secretion and an important role in the insulin action or release. To elucidate these problems more clearly, a dose-dependent experiment of serotonin will be carried out. In addition, other types of serotonergic antagonist will be administered to the pancreas to clarify detailed serotonin action on pancreatic exocrine secretion. Moreover, this present study did not measure insulin volume in the perfusate. To measure accurately insulin volume will help to elucidate the insulin-serotonin relationship. Further study is necessary to study a insulin release for serotonin action mechanism.

ACKNOWLEDGEMENTS

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (KRF-2008-313-E00041). This research was partially supported by Hallym University Research Fund. 2010 (HRF-2010-034).

REFERENCES

19. Park HJ, Lee YL. Effect of reserpine on pancreatic exocrine


